CompletedPhase 2NCT01693783
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer
Studying Adenocarcinoma of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Amit M Oza, MDUniversity Health Network Princess Margaret Cancer Center P2C
- Intervention
- Ipilimumab(biological)
- Enrollment
- 42 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2012 – 2021
Study locations (13)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- City of Hope South Pasadena, South Pasadena, California, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- Tom Baker Cancer Centre, Calgary, Alberta, Canada
- Cross Cancer Institute, Edmonton, Alberta, Canada
- BC Cancer Research Centre, Vancouver, British Columbia, Canada
- BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada
- Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
- London Regional Cancer Program, London, Ontario, Canada
- Ottawa Hospital and Cancer Center-General Campus, Ottawa, Ontario, Canada
- University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01693783 on ClinicalTrials.govOther trials for Adenocarcinoma of the cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07276360Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in UgandaUganda Cancer Institute
- RECRUITINGPHASE1NCT07454642AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid TumorsAvacta Life Sciences Ltd
- RECRUITINGPHASE3NCT07061977Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerNational Cancer Institute (NCI)
- RECRUITINGNCT07359586Laryngopharyngeal Injury After Endotracheal Intubation Under General AnesthesiaZhejiang University
- RECRUITINGPHASE1NCT07020117A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsAktis Oncology, Inc.
- RECRUITINGPHASE2NCT06654011IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 TrialUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07153952RT for Adenocarcinoma/Adenosquamous CarcinomaPeking Union Medical College Hospital
- RECRUITINGNCT06733740Ultrasound-guided Thermal Ablation for Papillary Thyroid CarcinomaChinese PLA General Hospital